Loading clinical trials...
Loading clinical trials...
A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients
Conditions
Interventions
dextromethorphan hydrobromide
morphine sulfate
Locations
4
Canada
Cross Cancer Institute
Edmonton, Alberta, Canada
Newfoundland Cancer Treatment and Research Foundation
St. John's, Newfoundland and Labrador, Canada
Princess Margaret Hospital
Toronto, Ontario, Canada
McGill University
Montreal, Quebec, Canada
Start Date
June 11, 1998
Primary Completion Date
September 26, 2001
Completion Date
February 10, 2009
Last Updated
April 3, 2020
NCT06735690
NCT07249528
NCT04570423
NCT00131014
NCT05564390
NCT03050268
Lead Sponsor
NCIC Clinical Trials Group
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions